Login / Signup

TGM4: an immunogenic prostate-restricted antigen.

Zoila A Lopez-BujandaAleksandar Z ObradovicThomas R NirschlLaura CrowleyRodney MacedoAlexandros PapachristodoulouTimothy O'DonnellUri LasersonJelani C ZarifRan ReshefTiezheng YuanMithil K SoniEmmanuel S AntonarakisMichael C HaffnerH Benjamin LarmanMichael M ShenPawel MuranskiCharles G Drake
Published in: Journal for immunotherapy of cancer (2022)
These results suggest that TGM4 is an immunogenic, prostate-restricted antigen with the potential for further development as an immunotherapy target.
Keyphrases
  • prostate cancer
  • benign prostatic hyperplasia
  • risk assessment
  • human health
  • climate change